SMILES
stringlengths
2
1.49k
Question
stringlengths
40
251
Answer
stringlengths
1
191
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
7
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
Is the drug administered in this specific form, such as a particular salt?
Yes
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
Determine if this compound is a prodrug.
No
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase XII inhibitor
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
Which USAN substem can this drug or clinical candidate name be matched with?
-zolamide
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
What is the molecular weight of this compound's parent molecule?
222.25
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
What is the definition of this compound's USAN stem?
carbonic anhydrase inhibitors
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
How many heavy (non-hydrogen) atoms does this compound have?
13
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown.
Small molecule
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality.
An achiral molecule
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
6
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Does this compound satisfy the rule-of-three criteria?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase II inhibitor
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many hydrogen bond acceptors does this compound have?
4
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts?
0
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is it known whether this drug is administered parenterally?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is it known whether this drug is applied topically?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is this compound a small molecule polymer, such as polystyrene sulfonate?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)?
4
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is this molecule characterized by a small molecular structure or a protein sequence?
It has a small molecule structure.
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the calculated ALogP value for this compound?
0.29
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms.
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Approved
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase I inhibitor
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is there a black box warning associated with this drug?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications?
Yes
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase IV inhibitor
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)?
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the polar surface area (PSA) value of this compound?
120.32
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the first recorded year of approval for this drug?
1958
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many hydrogen bond donors does this compound have?
2
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound?
0
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many aromatic rings does this compound have?
1
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is this compound an acid, a base, or neutral?
NEUTRAL
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Determine the type of availability for this drug.
prescription only
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the molecular formula of this compound, including any salt that it may have?
C6H6Cl2N2O4S2
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many rotatable bonds does this compound have?
2
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is it known whether this drug is taken orally?
Yes
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the molecular weight of this compound's parent molecule?
305.16
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Is the drug administered in this specific form, such as a particular salt?
Yes
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Determine if this compound is a prodrug.
No
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase XII inhibitor
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown.
Small molecule
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
How many heavy (non-hydrogen) atoms does this compound have?
16
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the polar surface area (PSA) value of this compound?
115.04
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality.
An achiral molecule
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the calculated ALogP value for this compound?
-0.86
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Does this compound satisfy the rule-of-three criteria?
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase II inhibitor
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts?
0
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is it known whether this drug is applied topically?
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is this compound a small molecule polymer, such as polystyrene sulfonate?
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the first recorded year of approval for this drug?
1953
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is this molecule characterized by a small molecular structure or a protein sequence?
It has a small molecule structure.
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is it known whether this drug is administered parenterally?
Yes
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms.
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Approved
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase I inhibitor
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target?
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the molecular formula of this compound, including any salt that it may have?
C4H6N4O3S2
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many hydrogen bond acceptors does this compound have?
6
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is there a black box warning associated with this drug?
Yes
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications?
Yes
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)?
3
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase IV inhibitor
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)?
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many hydrogen bond donors does this compound have?
2
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound?
0
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many aromatic rings does this compound have?
1
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is this compound an acid, a base, or neutral?
NEUTRAL
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Determine the type of availability for this drug.
prescription only
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many rotatable bonds does this compound have?
2
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is it known whether this drug is taken orally?
Yes
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
7
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Is the drug administered in this specific form, such as a particular salt?
Yes
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Determine if this compound is a prodrug.
No
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Please provide a description of this drug's mechanism of action.
Carbonic anhydrase XII inhibitor
CC(=O)Nc1nnc(S(N)(=O)=O)s1
Which USAN substem can this drug or clinical candidate name be matched with?
-zolamide
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the molecular weight of this compound's parent molecule?
222.25
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the definition of this compound's USAN stem?
carbonic anhydrase inhibitors
CC(=O)Nc1nnc(S(N)(=O)=O)s1
How many heavy (non-hydrogen) atoms does this compound have?
13
CC(=O)Nc1nnc(S(N)(=O)=O)s1
What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown.
Small molecule
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality.
Single stereoisomer
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
What is the molecular formula of this compound, including any salt that it may have?
C22H19ClO3
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Does this compound satisfy the rule-of-three criteria?
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
3
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Is it known whether this drug is administered parenterally?
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Is it known whether this drug is applied topically?
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)?
1
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Is this compound a small molecule polymer, such as polystyrene sulfonate?
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Is this molecule characterized by a small molecular structure or a protein sequence?
It has a small molecule structure.
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms.
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Approved
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound?
1
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Is there a black box warning associated with this drug?
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
How many aromatic rings does this compound have?
2
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target?
No
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Please provide a description of this drug's mechanism of action.
Cytochrome b inhibitor
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
How many hydrogen bond acceptors does this compound have?
3